Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
13.56
+0.37 (2.81%)
Jun 29, 2026, 2:01 PM EDT - Market open
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
1.74B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Sarepta Therapeutics | 835 |
| Vir Biotechnology | 367 |
| UroGen Pharma | 298 |
| Zymeworks | 243 |
| Innoviva | 159 |
| Absci | 140 |
| Septerna | 130 |
MESO News
- 4 days ago - Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility - GlobeNewsWire
- 11 days ago - ASX 200 Climbs as Biotech and Mining Stocks Lead Gainers on June 18, 2026 - International Business Times (Australia)
- 27 days ago - Mesoblast Slides: Investor presentation - Filings
- 2 months ago - Mesoblast (MESO) Reports Strong Q1 Sales for Ryoncil® - GuruFocus
- 2 months ago - Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - GlobeNewsWire
- 2 months ago - Mesoblast Earnings release: Q3 2026 - Filings
- 2 months ago - Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 2 months ago - Mesoblast acquires chimeric antigen receptor platform technology - TheFly